WEST CHESTER, PA — Molecular Targeting Technologies Inc. (MTTI) will present clinical data from 81 patients at the 5th Targeted Radiopharmaceuticals Summit, offering evidence that its Evans Blue drug delivery platform may improve the efficiency of targeted radiopharmaceutical therapies while reducing the amount of radioactivity required for treatment.
The clinical-stage biotechnology company said the dataset, which it describes as the largest reported evaluation of an albumin-binding peptide receptor radionuclide therapy (PRRT), is intended to validate its Evans Blue platform, a reversible albumin-binding technology designed to extend drug circulation and increase tumor exposure.
According to MTTI, clinical imaging and dosimetry showed tumors retained the radiotherapeutic for up to 15 days following a single administration. The company reported approximately eightfold greater tumor uptake and retention than conventional lutetium-177 DOTA-TATE therapy and said comparable tumor radiation doses were achieved using about 12.5% of the cumulative administered radioactivity required by standard PRRT.
If confirmed in broader clinical testing, those findings could support efforts to improve the therapeutic efficiency of radiopharmaceuticals by modifying how long treatments remain available to tumors rather than relying solely on new molecular targets.
The company also reported preclinical data suggesting the Evans Blue platform may be applicable across multiple radionuclides and targeting ligands. In laboratory studies, Evans Blue-enabled compounds demonstrated tumor retention of up to 35 times that of conventional lutetium-177 DOTA-TATE, according to the company.
MTTI said its alpha-emitting candidate, 225Ac-EBTATE, produced antitumor activity comparable to RayzeBio’s RYZ101 while using approximately 40% of the administered radioactivity under the conditions evaluated. Additional preclinical studies showed 177Lu-EBTATE outperformed conventional 177Lu-DOTA-TATE in lung adenocarcinoma and pancreatic xenograft models, while 177Lu-EBRGD combined with anti-PD-1 immunotherapy achieved complete long-term survival in colorectal cancer models.
Norman LaFrance, M.D., the company’s chief strategy officer, said the 81-patient dataset represents what MTTI believes is the first clinical validation of reversible albumin binding as a pharmacokinetic strategy for targeted radiopharmaceuticals.
“Radiopharmaceutical oncology is entering a new era in which optimizing pharmacokinetics may become as important as discovering new molecular targets.”
MTTI said the Evans Blue platform is designed to function independently of a radiopharmaceutical’s targeting ligand, allowing it to be integrated with existing and investigational therapies across multiple molecular targets.
The company said it is seeking research, licensing and co-development partnerships with pharmaceutical and biotechnology companies interested in applying the platform to approved and investigational radiopharmaceutical programs.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.